No price history available.
Key financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | INRm | N/A | 6,790 | 49,144 | 47,405 | 41,004 | 41,237 | 43,881 | N/A | N/A |
| Operating profit | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | INRm | N/A | 544 | 4,767 | 3,075 | 1,829 | 2,512 | 2,779 | N/A | N/A |
| EPS reported | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | INRm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | INR | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in INR| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Jubilant Ingrevia Limited, established in 2019 and based in Noida, India, is a global supplier of life science products and comprehensive solutions. The company's operations are divided into three core divisions: Specialty Chemicals, Nutrition & Health Solutions, and Life Science Chemicals. The Specialty Chemicals segment delivers a variety of specialized ingredients, fine chemicals, and crop protection agents, in addition to offering custom development and manufacturing (CDMO) services. Its Nutrition & Health Solutions division focuses on ingredients for both human and animal nutrition and well-being. Meanwhile, the Life Science Chemicals segment provides crucial life science components and a range of specialized ethanol products. Jubilant Ingrevia's extensive portfolio encompasses numerous chemical offerings, including a broad spectrum of pyridine derivatives (such as picolines, cyanopyridines, and various substituted pyridines), essential vitamins like B3 and riboflavin phosphate sodium, and nutritional compounds like premixes and antioxidants. They also produce industrial chemicals like acetic anhydride, ethyl acetate, and various alcohols (absolute alcohol, ethanol), alongside biocompost and gas mixtures. Furthermore, the company supplies a wide array of animal health and nutrition additives, including mineral premixes, stress regulators, amino acids, herbal growth promoters, toxin binders, and enzymes. Beyond its product range, Jubilant Ingrevia offers specialized services in chemical synthesis, covering everything from initial route design and process optimization to scaling up production and commercial manufacturing of intermediates. The company serves a diverse client base across the pharmaceutical, nutrition, agrochemical, consumer goods, and industrial sectors. Originally incorporated as Jubilant LSI Limited, the company adopted its current name, Jubilant Ingrevia Limited, in October 2020.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Jubilant Ingrevia Limited (JUBLINGREA.NS)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Jubilant Ingrevia Limited, established in 2019 and based in Noida, India, is a global supplier of life science products and comprehensive solutions. The company's operations are divided into three core divisions: Specialty Chemicals, Nutrition & Health Solutions, and Life Science Chemicals. The Specialty Chemicals segment delivers a variety of specialized ingredients, fine chemicals, and crop protection agents, in addition to offering custom development and manufacturing (CDMO) services. Its Nutrition & Health Solutions division focuses on ingredients for both human and animal nutrition and well-being. Meanwhile, the Life Science Chemicals segment provides crucial life science components and a range of specialized ethanol products. Jubilant Ingrevia's extensive portfolio encompasses numerous chemical offerings, including a broad spectrum of pyridine derivatives (such as picolines, cyanopyridines, and various substituted pyridines), essential vitamins like B3 and riboflavin phosphate sodium, and nutritional compounds like premixes and antioxidants. They also produce industrial chemicals like acetic anhydride, ethyl acetate, and various alcohols (absolute alcohol, ethanol), alongside biocompost and gas mixtures. Furthermore, the company supplies a wide array of animal health and nutrition additives, including mineral premixes, stress regulators, amino acids, herbal growth promoters, toxin binders, and enzymes. Beyond its product range, Jubilant Ingrevia offers specialized services in chemical synthesis, covering everything from initial route design and process optimization to scaling up production and commercial manufacturing of intermediates. The company serves a diverse client base across the pharmaceutical, nutrition, agrochemical, consumer goods, and industrial sectors. Originally incorporated as Jubilant LSI Limited, the company adopted its current name, Jubilant Ingrevia Limited, in October 2020.